Saralasin acetate is an FDA-approved diagnostic agent for detecting angiotensin II-dependent hypertension, which may help identify potentially curable secondary causes of high blood pressure.
Answers are grounded in this paper and cite their sources.
May guide detection of curable secondary hypertension; leaves open validation against modern diagnostics.
Almost 60 million adults in the United States have arterial hypertension. Most will be judged to have primary (essential) hypertension and will, therefore, be consigned to a lifetime of physician visits and antihypertensive drug therapy to prolong life and reduce cardiovascular morbidity. The longterm cost, unpleasant or adverse side effects of lifelong antihypertensive drug therapy, and high rate of lack of adherence (with the possible associated reduced benefit) are adequate reasons to search for secondary potentially curable causes of high BP, of which the most prevalent is renovascular hypertension. Recently, saralasin acetate has been approved by the Food and Drug Administration for use as a diagnostic agent for the detection of angiotensin II-dependent (renin-mediated) hypertension. Most of the experimental and clinical studies of saralasin have been published in specialty journals, 1 so that many practicing physicians are unfamiliar with this drug or with its proper use. Therefore, a committee composed
No takes yet. Share an insight, caveat, or question.
Edward D. Fröhlich (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: